免疫・アレルギー疾患政策研究事業
（○：委員長）
| ○ | 市村 恵一 | 自治医科大学名誉教授、 東京みみ・はな・のどサージクリニック名誉院長 |
|
| 耳鼻咽喉科学 | |||
| ＜研究論文例＞ オスラー病の鼻出血に対する鼻粘膜皮膚置換術後にみられる再出血部位の検討. 市村 恵一日耳鼻2019;122（5）:764-769. |
|||
| ＜著作例＞ 新耳鼻咽喉科学 改訂12版 加我君孝編集：市村恵一他共著,南山堂.（2022） |
|||
| ＜著作例＞ Japanese Society of Allergology.：Japanese guidelines for allergic rhinitis 2020. Okubo K, Kurono Y, Ichimura K, et al.; Allergol Int. 2020;69(3):331-345. |
|||
| 興梠 博次 | 社会保険大牟田天領病院・病院長 | ||
| 呼吸器内科 | |||
| CD8 and CD103 are highly expressed in asthmatic bronchial intraepithelial lymphocytes, I Hirosako S, Goto E, Tsumori K, Fujii K, Hirata N, Ando M, Kohrogi H. Int Arch Allergy Immunol 2010, 153:157-165. | |||
| T cells of atopic asthmatics preferentially infiltrate into human bronchial xenografts in SCID mice, Tsumori K, Kohrogi H, Goto E, Hirata N, Hirosako S, Fujii K, Ando M, Kawano O, Mizuta H: J Immunol 2003, 170:5712-5718. | |||
| Allergen exposure induces the expression of endothelial adhesion molecules in passively sensitized human bronchus: time course and the role of cytokines, Hirata N, Kohrogi H, Iwagoe H, Goto E, Hamamoto J, Fujii K, Yamaguchi T, Kawano O, Ando M. Am J Respir Cell Mol Biol 1998, 18:12-20. | |||
| 桑名 正隆 | 日本医科大学大学院医学研究科 大学院教授 | ||
| アレルギー膠原病内科学 | |||
| ＜研究論文＞ Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380(26): 2518-2528. |
|||
| ＜研究論文＞ Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension in the modified intention-to-treat population of the AMBITION study: a post hoc analysis. Ann Rheum Dis 2020; 79(5): 626-634 |
|||
| ＜研究論文＞ Gono T, Masui K, Nishina N, Kawaguchi K, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, *Kuwana M, and A Multicenter Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) investigators. Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease. Arthritis Rheumatol. 2021; 73(4): 677-686. doi: 10.1002/art.41566. |
|||
| 竹内 勤 | 埼玉医科大学 副学長・慶應義塾大学 名誉教授 | ||
| リウマチ・膠原病学、臨床免疫学 | |||
| Smolen JS, Landewé R, Bijlsma J, Burmester G, Dougados M, Kershbaumer A, McInnes IB, Sepriano A, van Vollenhoven R, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Bush MH, Buttgreit F, Caporali R, Cardiel MH, De Coke D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg J-E, Hetland ML, Huizinga T, Kouloumas M, Li Z, Mariette Z, Muller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis, 79:685-99, 2020. | |||
| Choy E, de Benedetti F, Takeuchi T, Hashizume M, John MR, and Kishimoto T. Translating IL-6 biology into effective treatments. Nature Rev Rheum, 16:335-45, 2020 | |||
| Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T, and Yamada E. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean treatment with peficitinib) from a long term, open-label extension study in Japan, Korea and Taiwan. Arthritis Research and Therapy, 22:47, 2020. | |||
